CRO Sr. Scientist
Dr. Galina Strizheva leads the development and execution of
preclinical and clinical research projects, designs new assays and
implements new methodologies. She provides scientific and technical
expertise and assistance to variety of CRO projects. She also leads the
assay validation process and collaborates closely with our laboratory
Dr. Strizheva is an accomplished scientist with over 18 years of
experience as a researcher, scientific support and project leader within
the commercial, clinical and research organizations in the US and
Russian Federation, with expertise in immunology, molecular and cellular
biology. She received her MD in Research (Medical Biochemistry,
Molecular and Cell Biology) from the Russian State Medical University
and performed her graduate project at Fox Chase Cancer Center. Dr.
Strizheva continued her education in the US and received her MSc in
Pharmacology and Physiology from Saint Louis School of Medicine. For
the past six years, Dr. Strizheva worked within CRO organizations
leading cell biology and immunology projects and covering assay
development and validation for safety of biologics, tumor tolerance, and
immune checkpoint modulators. Prior to that, Dr. Strizheva provided
consultations, coaching and troubleshooting to the customers interested
in IHC, Flow Cytometry, FISH and CISH research, and diagnostic products
in the role of the Support Scientist at Life Technologies Corporation
(now part of the Thermo Fisher Corp.). At the beginning of her career,
Dr. Strizheva briefly worked in Investigative Toxicology department at
Amgen and cytogenetics clinical labs at Cardinal Glennon Children’s
Hospital and at Russian Children's Clinical Hospital.
Publications (limited selection)
Strizheva G, Randhawa A, Mulligan J, O’Day. Development of an in vitro pre-clinical cellular assay to predict induction of Cytokine Storm by therapeutic antibodies. The Journal of Immunology. 188, 125.16, 2012.
Strizheva G, Carsillo T, Kruger W, Sullivan E, Ryu J, Henske P. The Spectrum of Mutations in TSC1 and TSC2 in Women with Tuberous Sclerosis and Lymphangioleiomyomatosis. Am J Respir. Crit. Care Med. vol. 163 no. 1 253-258. January, 2001.
Khare L, Strizheva G, Bailey J, Au K, Northrup H, Smith M, Smalley S, Henske E. A
novel missense mutation in the GTPase activating protein homology
region of TSC2 in two large families with tuberous sclerosis complex. J Med Genet. 38:347–349, 2001.